ALNY Q4 2022 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$335M+29.6% YoY

Gross Profit

$284M84.7% margin

Operating Income

-$189M-56.3% margin

Net Income

-$207M-61.9% margin

EPS (Diluted)

$-1.68

QoQ Revenue Growth

+26.8%

Cash Flow

Operating Cash Flow

-$132M

Free Cash Flow

-$154M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$3.5B

Total Liabilities

$3.7B

Stockholders' Equity

-$158M

Cash & Equivalents

$866M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$335M	$259M	+29.6%
Gross Profit	$284M	$221M	+28.5%
Operating Income	-$189M	-$195M	+3.1%
Net Income	-$207M	-$258M	+19.7%

Revenue Segments

Product

$262M99%

Royalty

$3M1%

Geographic Segments

Europe

$13M54%

UNITED STATES

$9M37%

Non-US Or Europe

$2M9%